塞来昔布、萘普生或布洛芬治疗关节炎的心血管安全性
该随机试验纳入需使用非甾体抗炎药(NSAIDs)的骨关节炎或类风湿关节炎且心血管风险升高的患者,随机接受塞来昔布(平均日剂量209±37 mg)、萘普生(852±103 mg)或布洛芬(2045±246 mg)。主要复合终点为心血管死亡(包括出血性死亡)、非致死性心肌梗死或非致死性卒中。意向性治疗分析中,塞来昔布组主要终点事件发生率为2.3%,萘普生组2.5%,布洛芬组2.7%;塞来昔布对比萘普生的风险比(HR)为0.93(95%CI 0.76–1.13),对比布洛芬为0.85(95%CI 0.70–1.04),两项比较的非劣效性P值均<0.001。结论认为在中等剂量下,塞来昔布的心血管安全性不劣于布洛芬或萘普生。
要点
- 在心血管风险升高的关节炎患者中,塞来昔布(平均日剂量209±37 mg)主要心血管复合终点发生率为2.3%,萘普生(852±103 mg)为2.5%,布洛芬(2045±246 mg)为2.7%。
- 意向性治疗分析:塞来昔布对比萘普生的HR为0.93(95%CI 0.76–1.13),对比布洛芬的HR为0.85(95%CI 0.70–1.04),非劣效性P值均<0.001。
- 塞来昔布组胃肠道事件风险显著低于萘普生组(P=0.01)和布洛芬组(P=0.002)。
- 塞来昔布组肾脏事件风险显著低于布洛芬组(P=0.004),但对比萘普生组无显著差异(P=0.19)。
适用人群与场景
- 需要接受NSAIDs治疗的骨关节炎或类风湿关节炎患者,且心血管风险升高。
处置流程与药物剂量
- 塞来昔布组平均日剂量209±37 mg;萘普生组平均日剂量852±103 mg;布洛芬组平均日剂量2045±246 mg。
- 平均治疗持续时间20.3±16.0个月,平均随访时间34.1±13.4个月。
研究设计与关键结果
- 随机对照试验,共纳入24,081例患者,随机分入塞来昔布组、萘普生组或布洛芬组。
- 意向性治疗分析:主要终点事件在塞来昔布组发生188例(2.3%),萘普生组201例(2.5%),布洛芬组218例(2.7%);塞来昔布对比萘普生HR 0.93(95%CI 0.76–1.13),塞来昔布对比布洛芬HR 0.85(95%CI 0.70–1.04),非劣效性P值均<0.001。
- 在治疗分析:主要终点事件在塞来昔布组发生134例(1.7%),萘普生组144例(1.8%),布洛芬组155例(1.9%);塞来昔布对比萘普生HR 0.90(95%CI 0.71–1.15),塞来昔布对比布洛芬HR 0.81(95%CI 0.65–1.02),非劣效性P值均<0.001。
- 胃肠道事件风险:塞来昔布组显著低于萘普生组(P=0.01)和布洛芬组(P=0.002)。
- 肾脏事件风险:塞来昔布组显著低于布洛芬组(P=0.004),但对比萘普生组无显著差异(P=0.19)。
- 试验期间68.8%的患者停用研究药物,27.4%的患者失访。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 非劣效性界值:意向性治疗分析要求风险比≤1.12且97.5%置信区间上限≤1.33;在治疗分析要求97.5%置信区间上限≤1.40。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心血管风险升高的骨关节炎或类风湿关节炎患者,中等剂量塞来昔布(平均日剂量209±37 mg)的心血管安全性不劣于布洛芬(2045±246 mg)或萘普生(852±103 mg)。
- 塞来昔布组胃肠道事件风险显著低于萘普生和布洛芬,肾脏事件风险显著低于布洛芬。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain.
METHODS: Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen. The goal of the trial was to assess the noninferiority of celecoxib with regard to the primary composite outcome of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or nonfatal stroke. Noninferiority required a hazard ratio of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-treat population and of 1.40 or lower in the on-treatment population. Gastrointestinal and renal outcomes were also adjudicated.
RESULTS: A total of 24,081 patients were randomly assigned to the celecoxib group (mean [±SD] daily dose, 209±37 mg), the naproxen group (852±103 mg), or the ibuprofen group (2045±246 mg) for a mean treatment duration of 20.3±16.0 months and a mean follow-up period of 34.1±13.4 months. During the trial, 68.8% of the patients stopped taking the study drug, and 27.4% of the patients discontinued follow-up. In the intention-to-treat analyses, a primary outcome event occurred in 188 patients in the celecoxib group (2.3%), 201 patients in the naproxen group (2.5%), and 218 patients in the ibuprofen group (2.7%) (hazard ratio for celecoxib vs. naproxen, 0.93; 95% confidence interval [CI], 0.76 to 1.13; hazard ratio for celecoxib vs. ibuprofen, 0.85; 95% CI, 0.70 to 1.04; P<0.001 for noninferiority in both comparisons). In the on-treatment analysis, a primary outcome event occurred in 134 patients in the celecoxib group (1.7%), 144 patients in the naproxen group (1.8%), and 155 patients in the ibuprofen group (1.9%) (hazard ratio for celecoxib vs. naproxen, 0.90; 95% CI, 0.71 to 1.15; hazard ratio for celecoxib vs. ibuprofen, 0.81; 95% CI, 0.65 to 1.02; P<0.001 for noninferiority in both comparisons). The risk of gastrointestinal events was significantly lower with celecoxib than with naproxen (P=0.01) or ibuprofen (P=0.002); the risk of renal events was significantly lower with celecoxib than with ibuprofen (P=0.004) but was not significantly lower with celecoxib than with naproxen (P=0.19).
CONCLUSIONS: At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety. (Funded by Pfizer; ClinicalTrials.gov number, NCT00346216 .).
参考来源
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016. PMID: 27959716. doi:10.1056/NEJMoa1611593
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。